RNA Toxicity Pathway

RNA Toxicity Pathway

Overview

RNA toxicity encompasses a range of pathological mechanisms where abnormal RNA molecules, toxic gain-of-function from mutant proteins, or disruption of RNA metabolism lead to neuronal dysfunction and death. This pathway is particularly prominent in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and several spinocerebellar ataxias[@fibrinogen].

Pathway Overview

Key Molecular Players

RNA Toxicity Pathway

Overview

RNA toxicity encompasses a range of pathological mechanisms where abnormal RNA molecules, toxic gain-of-function from mutant proteins, or disruption of RNA metabolism lead to neuronal dysfunction and death. This pathway is particularly prominent in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and several spinocerebellar ataxias[@fibrinogen].

Pathway Overview

Key Molecular Players

| Protein/RNA | Function | Disease Association |
|-------------|----------|---------------------|
| [C9orf72](/genes/c9orf72) | Hexanucleotide repeat expansion | ALS/FTD |
| [TDP-43](/mechanisms/tdp-43-proteinopathy) | RNA-binding protein, splicing | ALS, FTD, AD |
| FUS | RNA-binding protein, transport | ALS, FTD |
| TIA1 | Stress granule formation | ALS, FTD |
| RAN Translation | Repeat-associated non-AUG translation | C9orf72 |
| Ataxins | Polyglutamine expansion | SCA1, 2, 3, 6, 7, 17 |

Pathophysiological Mechanisms

C9orf72 Hexanucleotide Repeat Expansion

The GGGGCC hexanucleotide repeat expansion in the first intron of the [C9orf72](/genes/c9orf72) gene is the most common genetic cause of familial ALS and FTD[@c9orf72_mechanism_2019]. This mutation leads to disease through three primary mechanisms:

RNA Toxicity: The expanded repeat RNA forms toxic RNA foci that sequester essential RNA-binding proteins, disrupting normal RNA metabolism. These foci accumulate in the nucleus and cytoplasm, interfering with splicing, transport, and translation of critical neuronal mRNAs.

Dipeptide Repeat Proteins (DPRs): Repeat-associated non-AUG (RAN) translation produces five dipeptide repeat proteins (poly-GA, poly-GR, poly-PR, poly-PA, poly-GP) from both sense and antisense transcripts[@DPR_toxicity_2022]. These DPRs are aggregation-prone and cause toxicity through multiple mechanisms including:

• Proteasome inhibition
• Nucleocytoplasmic transport disruption
• Stress granule formation
• Mitochondrial dysfunction

TDP-43 Proteinopathy

TDP-43 (TAR DNA-binding protein 43) is an RNA-binding protein that is pathologically aggregated in most ALS cases and approximately 50% of FTD cases[@tdp43_2023]. Key mechanisms include:

Cytoplasmic Aggregation: Pathological TDP-43 forms cytoplasmic inclusions that sequester normal TDP-43 and other RNA-binding proteins, disrupting RNA metabolism.

Nuclear Loss: TDP-43 nuclear clearance leads to loss of its normal splicing and RNA processing functions, resulting in aberrant splicing of target mRNAs.

Stress Granule Dysregulation: TDP-43 is recruited to stress granules during cellular stress, where its persistent aggregation may lead to toxic inclusions[@stress_granules_2024].

FUS-Mediated Neurodegeneration

Mutations in the [FUS](/genes/fus) gene cause a distinct form of ALS with early onset and rapid progression[@fus_mechanisms_2022]. FUS pathology involves:

Cytoplasmic Mislocalization: FUS mutations impair its nuclear localization signal (NLS), leading to cytoplasmic accumulation and aggregation.

Stress Granule Abnormalities: FUS-positive stress granules are more prone to solidify into irreversible aggregates, disrupting translation and RNA metabolism.

DNA Damage Response: FUS is involved in DNA damage repair, and its dysfunction leads to genomic instability in neurons.

Disease Mechanisms

ALS/FTD (C9orf72)

• GGGGCC hexanucleotide repeat expansion (100s-1000s)[@ginsenoside]
• Sense and antisense RNA foci in neurons
• Bidirectional transcription produces toxic RNA
• RAN translation generates dipeptide repeat proteins (DPRs)
• DPRs (poly-GA, poly-GR, poly-PR, poly-PA, poly-GP) cause toxicity

ALS (FUS)

• FUS mutations (R521C, P525L) cause cytoplasmic accumulation[@dnarna]
• Impaired nuclear import (defective NLS)
• Stress granule formation and persistence
• Disruption of RNA transport and local translation
• Mitochondrial dysfunction

Spinocerebellar Ataxias

• CAG repeat expansions in ataxin genes[@btk]
• RNA foci formation (ATXN2, ATXN10)[@sca2_2024]
• Toxic gain-of-function from mutant protein
• Disruption of calcium signaling
• Mitochondrial dysfunction

Alzheimer's Disease

• TDP-43 inclusions in 30-50% of AD cases[@breaking]
• Aβ affects RNA splicing
• Tau affects RNA transport
• Relationship with cognitive decline

Nucleocytoplasmic Transport Defects

One of the central mechanisms in RNA toxicity-mediated neurodegeneration is disruption of nucleocytoplasmic transport[@nucleocytoplasmic_2023]. Multiple disease mechanisms converge on this pathway:

Nuclear Pore Complex Integrity: DPRs, FUS aggregates, and TDP-43 inclusions can directly damage nuclear pore complex components.

Importin Dysfunction: RNA-binding protein aggregates sequester importins, impairing nuclear import of essential proteins.

Exportin Disruption: RAN translation products interfere with exportin-mediated nucleocytoplasmic transport.

Consequences: This leads to nuclear accumulation of cytoplasmic proteins, decreased nuclear import of transcription factors and RNA processing proteins, and eventual cellular dysfunction and death.

Stress Granule Pathology

Stress granules are membrane-less organelles that form in response to cellular stress and dissolve when stress resolves[@stress_granules_2024]. In neurodegeneration, stress granules become pathological:

Persistent Granules: In disease states, stress granules fail to dissolve properly, becoming stable inclusions.

Sequestration of Essential Proteins: Pathological stress granules sequester TIA1, G3BP1, and other RNA-binding proteins, disrupting normal RNA metabolism.

Transition to Aggregation: Persistent stress granules can transition into irreversible protein aggregates characteristic of neurodegeneration.

RNA Foci Formation

RNA foci represent another pathological hallmark of repeat expansion diseases[@rna_foci_2023]. These nuclear or cytoplasmic accumulations of expanded repeat RNA:

Protein Sequestration: RNA foci sequester essential splicing factors, including TDP-43, hnRNPs, and SRSF proteins.

Splicing Dysregulation: Loss of splicing factors leads to aberrant splicing of multiple neuronal transcripts.

Toxic Gain-of-Function: The foci themselves may directly interfere with nuclear processes.

RAN Translation

Repeat-associated non-AUG (RAN) translation produces proteins from expanded repeats without a start codon[@ran_translation_2022]. This mechanism:

Bidirectional Translation: RAN translation occurs in both sense and antisense directions, producing multiple toxic proteins.

Aggregation-Prone Products: DPRs are highly aggregation-prone, forming intracellular inclusions.

Cellular Toxicity: Each DPR has distinct toxic properties affecting different cellular pathways.

Recent Discoveries (2024)

Nuclear Speckle Disruption

Recent research has revealed that C9orf72 repeat expansions disrupt nuclear speckle integrity, leading to widespread RNA splicing dysregulation[@nuclear_speckle_2024]. Nuclear speckles are membraneless organelles that serve as hubs for RNA processing and splicing factor storage. The expanded GGGGCC repeats:

• Form abnormal RNA structures that interact with speckle components
• Cause mislocalization of key splicing regulators
• Lead to aberrant alternative splicing of neuronal transcripts
• Contribute to the selective vulnerability of neurons in ALS/FTD

EXOC2 Regulation of Repeat Toxicity

The exocyst complex component EXOC2 has been identified as a critical regulator of C9orf72 repeat toxicity[@exoc2_2024]. EXOC2:

• Controls the toxicity of expanded GGGGCC repeats through vesicle trafficking pathways
• Modulates DPR aggregation and secretion
• Affects neuronal susceptibility to RNA toxicity
• Represents a potential therapeutic target

Poly-GR Ribotoxic Stress

Poly-GR dipeptide repeats have been shown to impair translation elongation and induce ribotoxic stress through p38 MAPK activation[@poly_gr_2024]. This mechanism:

• Activates the ZAKalpha kinase pathway
• Leads to ribosomal stalling and collision
• Triggers integrated stress response
• Causes neuronal death that can be blocked by ZAKalpha knockdown

G-Quadruplex Structure

The hexanucleotide repeat RNA forms tetrameric G-quadruplex structures that are toxic in ALS/FTD[@gquadruplex_2024]. These structures:

• Form stable four-stranded RNA conformations
• Sequester RNA-binding proteins
• Represent potential small molecule targets
• Have been structurally characterized at high resolution

Therapeutic Strategies

Antisense Oligonucleptide Therapy

Antisense oligonucleotides (ASOs) represent the most advanced therapeutic approach for RNA toxicity disorders[@antisense_2023]:

Mechanism: ASOs bind to target RNA and promote its degradation or modulate splicing.

Clinical Success: Tofersen (BIIB055) has received regulatory approval for SOD1-associated ALS.

C9orf72-Targeted ASOs: Multiple ASOs targeting C9orf72 expansion RNA are in clinical trials (BIIB060, WVE-004).

Challenges: Efficient delivery to the CNS, off-target effects, and patient selection remain active areas of investigation.

Small Molecule Modulators

Several small molecule approaches are in development:

RNA-Binding Protein Modulators: Compounds that disrupt toxic RNA-protein interactions.

Stress Granule Modulators: Drugs promoting stress granule dissolution or preventing their pathological transition.

RAN Translation Inhibitors: Compounds reducing DPR production from expanded repeats.

Gene Therapy Approaches

Viral vector-mediated gene delivery offers potential for long-term treatment:

AAV-Mediated Delivery: AAV vectors can deliver therapeutic genes to neurons.

Gene Silencing: shRNA or siRNA approaches targeting mutant allele expression.

Gene Replacement: Delivering healthy gene copies for loss-of-function mechanisms.

Advanced Therapeutic Strategies (2024)

Recent advances have identified new therapeutic targets:

Artificial MicroRNA Approach: Artificial miRNAs can suppress C9orf72 variants and decrease toxic DPR production in vivo, representing a promising gene therapy strategy (PMID:37752346).

G-Quadruplex Targeting: Small molecules that bind to the G-quadruplex structures formed by expanded C9orf72 repeats can reduce RNA toxicity. Triplex-like antisense RNA ligands also show promise.

p38 Inhibition: Poly-GR-induced ribotoxic stress can be ameliorated through p38 kinase inhibition, representing a downstream therapeutic target.

ZAKalpha Targeting: Knockdown of ZAKalpha kinase is neuroprotective against poly-GR toxicity, providing another target.

Clinical Trials

| Treatment | Target | Status | Indication |
|-----------|--------|--------|------------|
| Tofersen | SOD1 | Approved | ALS |
| BIIB060 | C9orf72 | Phase 1 | ALS/FTD |
| WVE-004 | C9orf72 | Phase 1 | ALS/FTD |
| ASO for ATXN2 | ATXN2 | Phase 1 | SCA2 |
| Reldesemtide | SOD1 | Phase 3 | ALS |
| Nobutra | TDP-43 | Preclinical | ALS/FTD |

Biomarkers

Fluid Biomarkers

• CSF dipeptide repeat proteins (C9orf72)[@biomarker_2024]
• TDP-43 in CSF
• Neurofilament light chain (NfL)
• Neurofilament phosphorylated heavy chain (pNfH)

Genetic Biomarkers

• Genetic testing for repeat expansions
• C9orf72 repeat size assessment

Imaging Biomarkers

• PET markers for stress granules
• White matter integrity (DTI)
• Motor cortex hyperexcitability (TMS)

Clinical Features and Diagnosis

ALS Clinical Features

Progressive muscle weakness, atrophy, fasciculations, and spasticity characterize ALS[@als_clinical_2023]. Upper motor neuron signs (brisk reflexes, spasticity) and lower motor neuron signs (weakness, atrophy, fasciculations) coexist.

FTD Clinical Features

Frontotemporal dementia presents with progressive changes in personality, behavior, and language[@ftd_mechanisms_2024]. Behavioral variant FTD and primary progressive aphasia are the main subtypes.

Diagnostic Criteria

Awareness El Escorial Criteria (modified):

• Progressive motor decline
• Presence of upper and lower motor neuron signs
• Exclusion of alternative diagnoses
• Neurophysiological evidence of denervation

Cross-Links

• Related to: [RNA Metabolism Dysregulation](/mechanisms/rna-metabolism-dysregulation)
• [Related to: [ALS Pathway](/mechanisms/als-pathway)](/diseases/amyotrophic-lateral-sclerosis)
• [Related to: [FTD Pathway](/mechanisms/frontotemporal-dementia-pathway)](/diseases/frontotemporal-dementia)
• Related to: [Stress Granules](/mechanisms/stress-granules)
• Related to: [Protein Quality Control](/mechanisms/protein-quality-control-network)
• Genes: [C9orf72 Gene](/genes/c9orf72), [FUS Gene](/genes/fus), [TARDBP Gene](/genes/tardbp), [ATXN10 Gene](/genes/atxn10)

See Also

• [RNA Metabolism Dysregulation](/mechanisms/rna-metabolism-dysregulation)
• [ALS Pathway](/mechanisms/als-pathway)
• [FTD Pathway](/mechanisms/frontotemporal-dementia-pathway)
• [Stress Granules](/mechanisms/stress-granules)
• [Protein Quality Control Network](/mechanisms/protein-quality-control-network)
• [C9orf72 Gene](/genes/c9orf72)
• [FUS Gene](/genes/fus)
• [TARDBP Gene](/genes/tardbp)
• [ATXN10 Gene](/genes/atxn10)

External Links

• [RNA Toxicity in Neurodegenerative Disease (Nature Reviews)](https://www.nature.com/articles/s41582-019-0262-8)
• [C9orf72 Hexanucleotide Repeat Expansions (Neuron)](https://www.sciencedirect.com/science/article/pii/S0896627311009293)
• [ALS Genetics Database](https://alsod.iop.kcl.ac.uk/)

Recent Research Updates (2024-2026)

• [Fibrinogen exacerbates α-synuclein aggregation and mitochondrial dysfunction via alpha5beta3 integrin in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/40425084/) (2026 Mar) - Journal of advanced research
• [Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS](https://pubmed.ncbi.nlm.nih.gov/41763422/) (2026 Feb 26) - International journal of biological macromolecules
• [The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease](https://pubmed.ncbi.nlm.nih.gov/41736445/) (2026 Feb 24) - Brain pathology
• [BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis](https://pubmed.ncbi.nlm.nih.gov/41710977/) (2026 Feb 19) - Brain
• [Breaking β-sheets in FUS prion-like domain preserves phase separation and function but prevents aggregation and toxicity](https://pubmed.ncbi.nlm.nih.gov/41756850/) (2026 Feb 18) - bioRxiv
• [Disruption of nuclear speckle integrity dysregulates RNA splicing in C9ORF72-FTD/ALS](https://pubmed.ncbi.nlm.nih.gov/39181135/) (2024) - Neuron
• [EXOC2 regulates toxicity of expanded GGGGCC repeats in C9ORF72-ALS/FTD](https://pubmed.ncbi.nlm.nih.gov/38935506/) (2024) - Cell Reports
• [Poly-GR repeats impair translation elongation and induce ribotoxic stress](https://pubmed.ncbi.nlm.nih.gov/39106320/) (2024) - Science Signaling

References

Phase Separation in RNA Toxicity

Biomolecular condensation through phase separation has emerged as a key mechanism in RNA toxicity. [@phase_separation_2024]

Liquid-Liquid Phase Separation

Stress Granule Formation:

• Stress granules form via LLPS
• RNA-binding proteins drive condensation
• Mutations affect phase behavior
• Pathological transition from liquid to solid

Therapeutic Implications

• Targeting phase transition
• Modulating material properties
• Preventing irreversible aggregation

DNA Damage Response in ALS/FTD

RNA-binding proteins play roles in DNA repair. [@dna_damage_2024]

Genomic Instability

FUS in DNA Repair:

• FUS localizes to DNA damage sites
• Mutant FUS impairs repair
• Accumulation of DNA damage
• Neuronal vulnerability

• TDP-43 affects DNA repair gene expression
• Loss of function contributes to pathology
• Therapeutic implications

RNA Metabolism in Neurodegeneration

RNA Splicing Dysregulation

Splicing Factors:

• SRSF proteins are sequestered
• hnRNPs are affected
• Alternative splicing alterations
• Cryptic splicing events

RNA Transport and Local Translation

Axonal RNA Biology:

• RNA transport to synapses
• Local translation regulation
• Transport deficits in disease
• Synaptic dysfunction contributions

Huntington's Disease and RNA Toxicity

Although primarily a protein aggregation disease, HD involves RNA mechanisms:

Mutant Huntingtin RNA Interactions

• Abnormal RNA binding
• Toxic gain-of-function
• Splicing alterations

SIDT2 in HD

Recent research identifies SIDT2 as a novel RNA autophagy protein in HD pathology.

Cross-Linked Pathways

• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [C9orf72 Mechanism](/genes/c9orf72)
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granules)
• [ALS Mechanisms](/mechanisms/amyotrophic-lateral-sclerosis-mechanisms)
• [FTD Mechanisms](/mechanisms/frontotemporal-dementia-mechanisms)

RNA Toxicity in Alzheimer's Disease

Although AD is primarily driven by amyloid-beta and tau pathology, RNA metabolism is also affected:

TDP-43 in AD

• TDP-43 inclusions found in 30-50% of AD cases
• Co-pathology with limbic-predominant age-related TDP-43 encephalopathy (LATE)
• Affects cognitive trajectory
• Interaction with tau pathology

RNA Binding Proteins in AD

• AD-related changes in RNA splicing
• Effects on APP processing RNA
• Tau affects RNA transport
• Synaptic RNA metabolism deficits

Mouse Models of RNA Toxicity

C9orf72 Models

Transgenic Approaches:

• BAC transgenic mice with human C9orf72
• Knock-in models with expanded repeats
• Show RNA foci and DPRs
• Motor and cognitive phenotypes

• Age-dependent motor deficits
• Nuclear import defects
• Stress granule formation
• Gliosis and inflammation

TDP-43 Models

Transgenic Models:

• TDP-43 overexpression models
• Mutant TDP-43 knock-in
• Show cytoplasmic inclusions
• Motor neuron pathology

• Nuclear loss is sufficient for toxicity
• Aggregate formation is toxic
• Glial contributions matter

Biomarker Development for RNA Toxicity

Fluid Biomarkers

CSF Markers:

• Dipeptide repeat proteins (poly-GA, poly-GP)
• TDP-43 fragments
• Neurofilament light chain
• pNfH for disease progression

• Extracellular RNA signatures
• Exosome cargo analysis
• Neurofilament measurements

Imaging Biomarkers

PET Tracers:

• Stress granule PET ligands
• TDP-43 binding compounds
• Under development

• Frontotemporal atrophy patterns
• White matter changes
• Diffusion tensor imaging alterations

Treatment Approaches Under Development

RNA-Targeted Therapies

Antisense Oligonucleotides:

• Target C9orf72 expansion RNA
• Reduce RNA foci formation
• Decrease DPR production
• Currently in clinical trials

• Correct aberrant splicing
• Target downstream effects
• Example: TDP-43 mis-splicing

Small Molecule Approaches

Phase Separation Modulators:

• Alter material properties of granules
• Prevent pathological transition
• Currently preclinical

• Reduce DPR production
• Target initiation mechanisms
• Promising preclinical data

Gene Therapy

AAV-Delivered shRNA:

• Silence mutant allele expression
• Reduce toxic RNA and protein
• Challenges with delivery

• Allele-specific editing
• Reduce repeat expansion
• Emerging technology

Protein Homeostasis and RNA Toxicity

Proteostasis Network

The proteostasis network is affected in RNA toxicity:

Protein Quality Control:

• Ubiquitin-proteasome system impaired
• Autophagy is dysregulated
• Aggregate formation increases

• Heat shock proteins affected
• Nascent protein handling impaired
• Aggregate clearance reduced

Therapeutic Implications

• Enhancing protein clearance
• Improving proteostasis capacity
• Targeting aggregation pathways

Synaptic Dysfunction in RNA Toxicity

Synaptic RNA Biology

• Local translation at synapses
• RNA transport to terminals
• Synaptic protein synthesis dysregulation
• Contributes to circuit dysfunction

Postsynaptic Effects

• NMDA receptor dysfunction
• AMPAR trafficking alterations
• Synaptic plasticity impairment
• Network hyperexcitability

Cellular Energy and RNA Toxicity

Mitochondrial Function

• Mitochondrial dysfunction in ALS/FTD
• Energy deficits affect RNA metabolism
• Calcium dysregulation
• Contributes to neuronal death

Metabolic Changes

• Glucose metabolism alterations
• Lipid metabolism changes
• Energy sensor pathway dysregulation
• Therapeutic targeting potential